LeBlanc, T., Ali, A., Campbell, V., Chan, O., Coats, T., Cole, D., … Mehta, P. (2025). Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies. In Blood (Vol. 146, pp. 5215–5215). American Society of Hematology. https://doi.org/10.1182/blood-2025-5215

LeBlanc, Thomas, Amir Ali, Victoria Campbell, Onyee Chan, Thomas Coats, Doria Cole, Daniel Cuadras, et al. “Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies.” In Blood, 146:5215–5215. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-5215.

LeBlanc T, Ali A, Campbell V, Chan O, Coats T, Cole D, et al. Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies. In: Blood. American Society of Hematology; 2025. p. 5215–5215.

LeBlanc, Thomas, et al. “Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 5215–5215. Crossref, doi:10.1182/blood-2025-5215.

LeBlanc T, Ali A, Campbell V, Chan O, Coats T, Cole D, Cuadras D, Cunningham N, Floisand Y, Flynn G, Gonzalez-Lugo J, Hodgson K, Khan A, Koenig K, Lai C, Legg A, Lo M, Lopez A, Lynam M, Maddox J, Nagumantry S, Newman M, O’Nions J, Park S, Pedrós M, Piccoli G, Stricherz M, Taussig D, Wagner C, Wang E, Whitmill R, Yaghmour G, Zhao R, Mehta P. Effectiveness and safety of CPX-351 in younger patients <60 years with newly diagnosed secondary Acute Myeloid Leukemia: Pooled analysis of US (V-RULES) and UK (CREST-UK) real-world studies. Blood. American Society of Hematology; 2025. p. 5215–5215.